Astria Therapeutics Inc

NASDAQ:ATXS   9:41:51 AM EDT
7.50
+0.13 (+1.76%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)426.69M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$16 Million
Adjusted EPS-$0.42
See more estimates
10-Day MA$7.34
50-Day MA$6.74
200-Day MA$6.58
See more pivots

Astria Therapeutics Inc Stock, NASDAQ:ATXS

22 Boston Wharf Road, 10th floor, Boston, Massachusetts 02210
United States of America
Phone: +1.617.349.1971
Number of Employees: 59

Description

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.